Paul Hastings LLP advised J.P. Morgan Securities and the other underwriters in connection with Lexeo Therapeutics’ approximately $100 million initial public offering of common stock and listing on the Nasdaq Global Market (Nasdaq: LXEO). Lexeo Therapeutics is a clinical-stage genetic medicine company based in New York. 

Partner and co-head of Equity Capital Markets and co-chair of the Corporate Life Sciences Group Seo Salimi and Securities and Capital Markets partner Will Magioncalda led the Paul Hastings team, which also included associate Chris Guerin.

More information on the transaction can be found here.                                                     

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.